Clínic Barcelona

Glucagon like peptide-1 may not be related with type 2 diabetes resolution after Gastric Bypass

Glucagon like peptide-1 (GLP-1) is a gut hormone related to insulin sensitivity. It has been suggested as a major factor for the improved glucose tolerance ensuing after Roux-en-Y Gastric Bypass (RYGBP) surgery. In this procedure, a stomach pouch is connected directly to the small intestine just beyond the duodenum. The remaining small intestine, with the rest of the stomach attached, is connected into a lower part of the intestine creating the "Y" shape that gives the technique its name. A work published in Diabetes Care suggests that the resolution of type 2 diabetes after RYGBP may be explained by mechanisms beyond enhancement of GLP-1 action. The first author of the paper is Dr. Amanda Jiménez, and Dr. Josep Vidal is the latter, both from the IDIBAPS team Diabetes: metabolic and molecular networks and the Endocrinology Service of the Hospital Clínic of Barcelona directed by Dr. Vidal.